Literature DB >> 7832798

Susceptibility of human T-lymphotropic virus type I infected cell line MT-2 to hepatitis C virus infection.

N Kato1, T Nakazawa, T Mizutani, K Shimotohno.   

Abstract

To obtain a hepatitis C virus (HCV) proliferation system, we examined the susceptibility of various cultured cell lines to HCV infection. We found that a human T-lymphotropic virus type I infected cell line MT-2 was fairly sensitive to HCV infection. Using the polymerase chain reaction, intracellular positive-stranded HCV RNA was detected until at least 15 days postinoculation (p.i.). Intracellular negative-stranded HCV RNA was also detected at 10 days p.i., although not at 7 days p.i., suggesting that HCV is replicating in MT-2 cells 10 days p.i. Sequence analysis of hypervariable region 1 (HVR1) revealed that HVR1 sequences from cells 10 days p.i. had become homogeneous, although HVR1 sequences from the inoculum showed the typical quasi-species. We also found a lack of anti-HVR1 antibody against the HVR1 species which became homogeneous at 10 days p.i., although we easily detected antibody against the other HVR1 species obtained from the inoculum. These findings suggest that MT-2 cells are susceptible to HCV infection and are capable of supporting HCV replication.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7832798     DOI: 10.1006/bbrc.1995.1123

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  31 in total

1.  Transfection of HepG2 cells with infectious hepatitis C virus genome.

Authors:  S Dash; A B Halim; H Tsuji; N Hiramatsu; M A Gerber
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

Review 2.  Cell culture systems for the hepatitis C virus.

Authors:  Gilles Duverlie; Czeslaw Wychowski
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

3.  Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry.

Authors:  Claire Bertaux; Tatjana Dragic
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

4.  Structure of the 3' terminus of the hepatitis C virus genome.

Authors:  T Tanaka; N Kato; M J Cho; K Sugiyama; K Shimotohno
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

5.  In vitro inhibition of hepatitis C virus gene expression by chemically modified antisense oligodeoxynucleotides.

Authors:  O Vidalin; M E Major; B Rayner; J L Imbach; C Trépo; G Inchauspé
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

6.  The native form and maturation process of hepatitis C virus core protein.

Authors:  K Yasui; T Wakita; K Tsukiyama-Kohara; S I Funahashi; M Ichikawa; T Kajita; D Moradpour; J R Wands; M Kohara
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

7.  Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C.

Authors:  Tram N Q Pham; Sonya A MacParland; Patricia M Mulrooney; Helen Cooksley; Nikolai V Naoumov; Tomasz I Michalak
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

8.  CD81 is required for hepatitis C virus glycoprotein-mediated viral infection.

Authors:  Jie Zhang; Glenn Randall; Adrian Higginbottom; Peter Monk; Charles M Rice; Jane A McKeating
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  Characterization of long-term cultures of hepatitis C virus.

Authors:  N Nakajima; M Hijikata; H Yoshikura; Y K Shimizu
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

10.  L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus.

Authors:  Emmanuel G Cormier; Robert J Durso; Fotini Tsamis; Lise Boussemart; Catherine Manix; William C Olson; Jason P Gardner; Tatjana Dragic
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.